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Proarrhythmic Effect of ICD Function
Athanasios G. Manolis, MD, Constantinos C. Akridas, MD,  
Zenon S. Kyriakides, MD
The implantable cardioverter – defibrillator (ICD) is a device that treats ventricular 
tachyarrhythmias (VT), when they appear in a sustained form. The device’s program-
ming can deliver the following therapies: 1) antitachycardia pacing (ATP), 2) cardio-
version and 3) defibrillation. Today’s devices also have the capability of every mode of 
cardiac pacing, i.e. atrial, ventricular, atrio-ventricular and biventricular pacing.
It is well known that the antiarrhythmic drug therapy can exhibit proarrhythmic 
effects. Likewise, the antiarrhythmic apparatus can possibly aggravate an existing 
VT or cause the appearance of a new arrhythmia, attempting to convert the clinical 
tachyarrhythmia.
A case of proarrhythmic effect related to the therapeutic sequences delivered by 
an ICD, is delineated in the following continuous recording of an arrhythmic event, 
as it was stored in the Holter function of the device.
It is about a patient with ischemic cardiomyopathy, low ejection fraction 
(LVEF=30%), sustained VT recorded on ambulatory monitoring, in whom a single 
chamber ICD was implanted.
On the upper left quadrant there is the arrhythmia episode report, including the 
treatment details of the VT detected by the device. The rest of the slide (panels A to 
F) represents the continuous tracing of the arrhythmic event, recalled from the device’s 
memory. Each panel consists of the endocardiac ventricular electrogram (EGM) and 
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the detected cardiac rhythm cycle length (in ms).
On panel A, the basic paced rhythm (60 bpm) and a pre-
mature ventricular contraction (PVC) is recorded. On panel 
B, it is a PVC that induces a sustained VT at a rate of 185 bpm. 
The first ATP scheme is released (arrow 1) with no effect. On 
panel C, the ICD attempts to terminate the VT by a second 
ATP sequence (arrow 2), resulting in a slight acceleration of 
the ventricular rate (11 bpm). The third ATP scheme (panel 
D, arrow 3) is followed by a significant acceleration of the 
tachycardia rate (240 – 250 bpm), which caused the device to 
defibrillate (panel E, arrow 4). Consecutively, the VT degener-
ated into ventricular fibrillation (panel F) and finally, a second 
shock of 30J (arrow 5) restored the regular rhythm.
In the former example, the ICD caused worsening of the 
existing VT, before it succeeded in terminating it, in the end. 
This demonstrates a proarrhythmic effect of the antiarrhyth-
mic device.
Arrhythmogenic effects of the delivered therapies in 
patients with implanted defibrillating systems have been 
recorded at a rate of 5 %. Directly related to the appearance 
of proarrhythmic effect are in general the following factors: 
1) high frequency of clinical VT, 2) rate of aggressiveness of 
the preprogrammed ATP protocol, 3) degree of myocardial 
dysfunction, 4) existence of myocardial ischemia, 5) coexist-
ence of electrolyte disorders1,2,3.
r E f E r E N c E s
 1 Fischer JD, Kim SG, Matos JA, et al. Comparative effective-
ness of pacing techniques for termination of well-tolerated sus-
tained ventricular tachycardia. PACE 183;6:15-20.
 2 Fischer JD, Johnston DR, Furman S, et al. Long-term efficacy 
of antitachycardia pacing for supraventricular and ventricular 
tachycardias. Am J Cardiol 187;60:1311-1316,
 3 Kappenberger L, Bufalo A, Fromer M. Termination and ac-
celeration of ventricular tachycardia during antitachycardia 
pacing, in Luderitz B, Saksena S (eds), Interventional Electro-
physiology, Futura, 11, p.p. 225-231.
